Aardvark Therapeutics, Inc. Common Stock

AARD

NASDAQ · Biotechnology

$1.45

At close - Oct 23, 4:00 PM EDT - USD

Market Cap$32M

P/E-0.5x

52W High$16.60

Volume15.78M

VCP Research Verdict2026Q1

Accelerating Clinical Spend Pressures Capital Runway

Aardvark Therapeutics is currently in a high-stakes transition toward Phase III clinical execution, characterized by a rapid escalation in R&D spending that has reached $16.6 million per quarter as of 2026Q1. While the company's focus on its lead metabolic can...

GrowthMixed

ProfitabilityNegative

ValuationReview

TechnicalsWeak

Explore valuation models

MARKET ACTION

AARD price & volume

Price trend, volume and key moving averages

Launch Terminal

Loading chart...

Market performance

Price History →

Trailing total returns as of 10/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return

AARD-89.00%

S&P 500 (^GSPC)+11.24%

1-Year Return

AARD-86.63%

S&P 500 (^GSPC)+13.13%

3-Year Return

AARD-89.86%

S&P 500 (^GSPC)+10.33%

5-Year Return

AARD-89.86%

S&P 500 (^GSPC)-15.24%

Growth & profitability

Annual revenue & EPS trend

Revenue

Net income

-$58M-179.7% YoY

Free cash flow

-$54M-198.2% YoY

Operating margin

ROIC (TTM)-

Avg ROIC 5Y-

ROE (TTM)-221.5%

Piotroski Score2 / 9

Financial Statements →

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History

EPS Beat Rate3/12 (38%)

Quarter	EPS (Act vs Est)	Revenue (Act vs Est)
Q3 2026Latest Aug 11, 2026	-$0.66+24.5% vs -$0.87	— vs —
Q2 2026 May 7, 2026	-$0.99-12.9% vs -$0.88	— vs —
Q2 2026 Mar 23, 2026	-$0.81+2.1% vs -$0.83	— vs —
Q4 2025 Nov 13, 2025	-$0.75+6.1% vs -$0.80	— vs —

Historical baseline: 12 quarters analyzedGAAP / Adjusted

MARKET COVERAGE

Latest News

5 Stories

Globe News Wire·Oct 15, 2026

Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf

PHILADELPHIA, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (NASDAQ: AARD): Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company's February 13, 2025, initial public offering (IPO) and have continued to hold their shares.

GlobeNewsWire·Sep 18, 2026

Lowey Dannenberg, P.C. is Investigating Aardvark Therapeutics, Inc. (NASDAQ: AARD) for Potential Violations of the Federal Securities Laws

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C.

PRNewsWire·Sep 10, 2026

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Aardvark Therapeutics, Inc. (AARD) to Contact Law Firm

NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Moore Law, PLLC, a shareholder litigation law firm located on Wall Street, is investigating potential claims against the officers and directors of Aardvark Therapeutics, Inc. (NASDAQ: AARD): Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders should email [email protected] What is the Investigation About?

GlobeNewsWire·Aug 11, 2026

Aardvark Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

Assessing unblinded Phase 3 HERO and OLE data for ARD-101 in PWS in the third quarter of 2026 to support an informed determination of next steps

Filtered for Aardvark Therapeutics, Inc. Common StockMore Headlines

Compare before deciding

Benchmark AARD against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Aardvark Therapeutics, Inc. Common Stock (AARD)

Full Screener →

Company	Price	Market Cap	P/E Ratio	Rev Growth (1Y)	Net Margin	ROE	Div Yield
AARDAardvark Therapeutics, Inc. Common StockCurrent	$1.45	$31.75M	-0.55	—	—	-221.55%	—
RYTMRhythm Pharmaceuticals, Inc.	$89.27	$6.12B	-28.70	45.83%	-85.59%	-80.48%	—
VNDAVanda Pharmaceuticals Inc.	$4.01	$241.14M	-1.07	8.72%	-127.41%	-84.95%	—
IMVTImmunovant, Inc.	$28.41	$5.86B	-10.26	—	-7585.86%	-69.59%	—
CGEMCullinan Therapeutics, Inc.	$14.37	$883.15M	-3.86	—	—	-52.89%	—
NUVLNuvalent, Inc.	$123.96	$9.13B	-21.19	—	—	-42.78%	—

Compare AARD vs Peers

Aardvark Therapeutics, Inc. Common Stock (AARD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs RYTM

Most directly comparable listed peer for AARD.

Scale Benchmark

vs LLY

Larger-name benchmark to compare AARD against a more recognizable public peer.

Peer Set

Compare Top 5

vs RYTM, VNDA, IMVT, CGEM

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

AARD SEC Filings & Documents

Aardvark Therapeutics, Inc. Common Stock (AARD) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

Material company update

Aug 17, 2026·SEC

Material company update

Aug 11, 2026·SEC

Material company update

Jun 12, 2026·SEC

10-K Annual Reports

FY 2026

Mar 23, 2026·SEC

FY 2025

Mar 31, 2025·SEC

10-Q Quarterly Reports

FY 2026

Aug 11, 2026·SEC

FY 2026

May 7, 2026·SEC

FY 2025

Nov 13, 2025·SEC

Get notified when AARD posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

AARD Frequently Asked Questions

Aardvark Therapeutics, Inc. Common Stock (AARD) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Is AARD profitable?

Aardvark Therapeutics, Inc. Common Stock (AARD) reported a net loss of $69.9M for fiscal year 2025.

Dividend & Returns

What is AARD's return on equity?

Aardvark Therapeutics, Inc. Common Stock (AARD) has a return on equity (ROE) of -221.5%. Negative ROE indicates the company is unprofitable.

What is Aardvark Therapeutics, Inc. Common Stock's free cash flow?

Aardvark Therapeutics, Inc. Common Stock (AARD) had negative free cash flow of $69.4M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in AARD back in 2022?

Total return calculator · dividends reinvested · 4+ years of data

See returns →

Quarter

EPS (Act vs Est)

Revenue (Act vs Est)

Q3 2026Latest

Aug 11, 2026

-$0.66+24.5%

vs -$0.87

—

vs —

Q2 2026

May 7, 2026

-$0.99-12.9%

vs -$0.88

—

vs —

Q2 2026

Mar 23, 2026

-$0.81+2.1%

vs -$0.83

—

vs —

Q4 2025

Nov 13, 2025

-$0.75+6.1%

vs -$0.80

—

vs —

Company

Price

Market Cap

P/E Ratio

Rev Growth (1Y)

Net Margin

ROE

Div Yield

AARDAardvark Therapeutics, Inc. Common StockCurrent

$1.45

$31.75M

-0.55

—

-221.55%

—

RYTMRhythm Pharmaceuticals, Inc.

$89.27

$6.12B

-28.70

45.83%

-85.59%

-80.48%

—

VNDAVanda Pharmaceuticals Inc.

$4.01

$241.14M

-1.07

8.72%

-127.41%

-84.95%

—

IMVTImmunovant, Inc.

$28.41

$5.86B

-10.26

—

-7585.86%

-69.59%

—

CGEMCullinan Therapeutics, Inc.

$14.37

$883.15M

-3.86

—

-52.89%

—

NUVLNuvalent, Inc.

$123.96

$9.13B

-21.19

—

-42.78%

—